NO20044452L - Oral administrering av epotiloner - Google Patents

Oral administrering av epotiloner

Info

Publication number
NO20044452L
NO20044452L NO20044452A NO20044452A NO20044452L NO 20044452 L NO20044452 L NO 20044452L NO 20044452 A NO20044452 A NO 20044452A NO 20044452 A NO20044452 A NO 20044452A NO 20044452 L NO20044452 L NO 20044452L
Authority
NO
Norway
Prior art keywords
epothilones
methods
oral administration
administered
relates
Prior art date
Application number
NO20044452A
Other languages
English (en)
Norwegian (no)
Inventor
Francis Y F Lee
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20044452L publication Critical patent/NO20044452L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO20044452A 2002-04-04 2004-10-19 Oral administrering av epotiloner NO20044452L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37010402P 2002-04-04 2002-04-04
PCT/US2003/009984 WO2003084536A1 (en) 2002-04-04 2003-04-01 Oral administration of epothilones

Publications (1)

Publication Number Publication Date
NO20044452L true NO20044452L (no) 2004-12-07

Family

ID=28792029

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044452A NO20044452L (no) 2002-04-04 2004-10-19 Oral administrering av epotiloner

Country Status (9)

Country Link
US (1) US6936628B2 (https=)
EP (1) EP1492529A1 (https=)
JP (1) JP2005527576A (https=)
AU (1) AU2003226189A1 (https=)
IS (1) IS7481A (https=)
NO (1) NO20044452L (https=)
PL (1) PL372773A1 (https=)
TW (1) TW200403994A (https=)
WO (1) WO2003084536A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
JP4808960B2 (ja) 2002-05-14 2011-11-02 エフ エム シー コーポレーション 微結晶質セルロース組成物
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
FR2878443B1 (fr) * 2004-08-03 2009-01-16 Promindus Actions Promotionnel Composition pharmaceutique, destinee a l'administration par voie orale de principe(s) actif(s) fortement gastro-labile(s et sa preparation
AR052142A1 (es) * 2004-11-18 2007-03-07 Bristol Myers Squibb Co Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
EP1674098A1 (en) * 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
US20060255258A1 (en) * 2005-04-11 2006-11-16 Yongdong Wang Chromatographic and mass spectral date analysis
US7879382B2 (en) * 2005-09-30 2011-02-01 Fmc Corporation Stabilizers and compositions and products comprising same
WO2008057266A2 (en) * 2006-10-27 2008-05-15 Fmc Corporation Dry granulation binders, products, and use thereof
EP2009114A1 (en) * 2007-06-29 2008-12-31 Bayer Schering Pharma Aktiengesellschaft Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones
TWI461213B (zh) 2009-11-05 2014-11-21 Fmc Corp 作為藥物賦形劑之微晶纖維素及磷酸鈣之組合物
TW201129386A (en) 2009-11-05 2011-09-01 Fmc Corp Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
CN102665764A (zh) * 2009-12-22 2012-09-12 Fmc有限公司 可用作可再压实药物赋形剂的微晶纤维素和碳酸钙组合物
AU2011255647A1 (en) 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
BR112014007366B1 (pt) 2011-10-05 2020-09-15 Dupont Nutrition Usa, Inc Processo para fabricar uma composição estabilizadora compreendendo extrusão em duas etapas, composição estabilizadora de celulose microcristalina e produto alimentício comestível e suspensão industrial compreendendo a mesma
ES2657648T3 (es) 2011-10-05 2018-03-06 Fmc Corporation Composición estabilizadora de celulosa microcristalina y carboximetilcelulosa co-reducida, método para elaborarla y usos
EP2787837B1 (en) 2011-12-09 2017-03-15 FMC Corporation Co-attrited stabilizer composition
GB2595203A (en) 2020-03-03 2021-11-24 Alkaloid Ad Skopje Formulation
CZ2020287A3 (cs) 2020-05-20 2021-12-01 Mendelova Univerzita V Brně Způsob přípravy nanokompozitního materiálu na bázi redukovaného grafen oxidu, dusičnanu stříbrného a octanu měďnatého, nanokompozitní materiál, přípravek jej obsahující a jeho použití
CN114727995B (zh) * 2020-09-02 2024-06-11 北京华昊中天生物医药股份有限公司 优替德隆的固体口服制剂

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
US5671397A (en) * 1993-12-27 1997-09-23 At&T Global Information Solutions Company Sea-of-cells array of transistors
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
DK1186606T4 (da) 1995-11-17 2011-12-05 Biotechnolog Forschung Gmbh Epothilonderivater, deres fremstilling og anvendelse
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
EP0923583A1 (de) 1996-08-30 1999-06-23 Novartis AG Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
DK1367057T3 (da) 1996-11-18 2009-01-19 Biotechnolog Forschung Gmbh Epothiloner E og F
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
PT975638E (pt) 1997-02-25 2002-12-31 Biotechnolog Forschung Mbh Gbf Epothilons modificados nas cadeias laterais
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
WO1998047891A1 (de) 1997-04-18 1998-10-29 Studiengesellschaft Kohle Mbh Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6384230B1 (en) 1997-07-16 2002-05-07 Schering Aktiengesellschaft Thiazole derivatives, method for their production and use
ES2290993T3 (es) 1997-08-09 2008-02-16 Bayer Schering Pharma Aktiengesellschaft Nuevos derivados de epotilona, proceso para su produccion y su utilizacion farmaceutica.
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
SK287775B6 (sk) 1998-02-05 2011-09-05 Novartis Ag Farmaceutická formulácia obsahujúca epothilon, infúzny roztok a použitie farmaceutickej formulácie
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
DE69927790T2 (de) 1998-02-25 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
WO2000000485A1 (de) 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
NZ511722A (en) 1998-11-20 2004-05-28 Kosan Biosciences Inc Recombinant methods and materials for producing epothilone and epothilone derivatives
CN1122668C (zh) 1998-12-22 2003-10-01 诺瓦提斯公司 环氧噻酮衍生物，其制备方法及其药物组合物
HK1040739A1 (zh) 1998-12-23 2002-06-21 Bristol-Myers Squibb Company 微生物转形方法，用以制造epothilone
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
YU59001A (sh) 1999-02-18 2005-07-19 Schering Ag. 16-halogen-epotilon-derivati, postupak za njihovo dobijanje i njihova farmaceutska primena
BR0008379A (pt) * 1999-02-22 2002-09-24 Biotechnolog Forschung Gmbh Epotilonas modificadas em c-21
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
AR023792A1 (es) 1999-04-30 2002-09-04 Bayer Schering Pharma Ag Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
PL363363A1 (en) 2001-02-20 2004-11-15 Bristol-Myers Squibb Company Epothilone derivatives for the treatment of refractory tumors
BR0207487A (pt) 2001-02-20 2004-08-10 Brystol Myers Squibb Company Método de tratamento de tumores em mamìferos e uso de compostos de epotilona
WO2002072085A1 (en) 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
TW200303202A (en) 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives

Also Published As

Publication number Publication date
EP1492529A1 (en) 2005-01-05
WO2003084536A1 (en) 2003-10-16
JP2005527576A (ja) 2005-09-15
US6936628B2 (en) 2005-08-30
IS7481A (is) 2004-09-30
US20030220378A1 (en) 2003-11-27
TW200403994A (en) 2004-03-16
PL372773A1 (en) 2005-08-08
AU2003226189A1 (en) 2003-10-20

Similar Documents

Publication Publication Date Title
NO20044452L (no) Oral administrering av epotiloner
YU58103A (sh) Farmaceutski preparati, dozirane forme i postupci za oralnu primenu epotilona
NO20084752L (no) Konjugater av aziridinayl-epotilonanaloger og farmasoytiske sammensetninger som inneholder disse
EA200600566A1 (ru) Быстрорастворимая лекарственная форма соединения, действующего на кальциевый рецептор
NO20043367L (no) Oralt farmasoytisk preparat
ATE402176T1 (de) Pyrrolidin- und azetidinverbindungen alsccr5- antagonisten
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
GEP20156348B (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
NO20050917L (no) Thiomolybdatanaloger og anvendelser derav
NO20080827L (no) Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
WO2005115470A3 (fr) COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE β-­CARBOLINE, ET LEUR UTILISATION POUR LE TRAITEMENT DES CANCERS
NO20053398L (no) Farmasoytiske preparater av sertaconazol for vaginal anvendelse.
ATE499939T1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
WO2007131070A3 (en) Compositions, dosage forms and methods of treating emesis
WO2010046933A3 (en) Pharmaceutical compositions of taste-masked linezolid
ATE495159T1 (de) Diaminocyclohexan- und diaminocyclopentanderivate
ATE410152T1 (de) Therapeutisches system mit amoxicillin und clavulansäure
TW200732304A (en) Piperidine derivatives
WO2005051349A3 (en) Pharmaceutical compositions of mirtazapine
DE602007007968D1 (de) Pharmazeutische Formulierungen mit Irbesartan
MX2008001608A (es) Piperazinas acetilenicas como antagonistas de receptor de glutamato metabotropico.
NO20083352L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
MY148584A (en) Composition of organic compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application